Clincosm LogoSign in Get a demo

ATACA: Analysis of Antihypertensive Treatment Efficacy

Sponsor
AstraZeneca (Industry)
Overall Status
Terminated
CT.gov ID
NCT00767247
Collaborator
(none)
2,000
Enrollment
13
Locations
9.1
Duration (Months)
153.8
Patients Per Site
17
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Analysis of antihypertensive treatment efficacy.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Analysis of Antihypertensive Treatment Efficacy
    Study Start Date :
    May 1, 2008
    Actual Primary Completion Date :
    Feb 1, 2009
    Actual Study Completion Date :
    Feb 1, 2009

    Arms and Interventions

    Arm Intervention/Treatment
    1

    Male or female with arterial hypertension

    Outcome Measures

    Primary Outcome Measures

    1. Analysis of antihypertensive treatment efficacy. [measurement BP: 3 visits for 3 month]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • arterial hypertension

    • intake of Atacand before study enrollment

    Exclusion Criteria:

    • hypersensitivity to candesartan or any other ingredient of Atacand

    • liver function impairment and/or cholestasis

    • severe renal insufficiency (serum creatinine > 265 µmol/L)

    • Pregnant and lactating women

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Research Site Arhangelsk Russian Federation
    2 Research Site Bryansk Russian Federation
    3 Research Site Domodedovo Russian Federation
    4 Research Site Dzerzhinsk Russian Federation
    5 Research Site Ekaterinburg Russian Federation
    6 Research Site Essentuki Russian Federation
    7 Research Site Georgievsk Russian Federation
    8 Research Site Irkutsk Russian Federation
    9 Research Site Kazan Russian Federation
    10 Research Site Samara Russian Federation
    11 Research Site Severodvinsk Russian Federation
    12 Research Site Vidnoe Russian Federation
    13 Research Site Volgograd Russian Federation

    Sponsors and Collaborators

    • AstraZeneca

    Investigators

    • Principal Investigator: Dmitry Zateyshchikov, MD, Prof, Federal State Institution of Russian President's General Management Department

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00767247
    Other Study ID Numbers:
    • NIS-CRU-ATA-2008/1
    First Posted:
    Oct 7, 2008
    Last Update Posted:
    Dec 3, 2010
    Last Verified:
    Dec 1, 2010
    Keywords provided by , ,
    Arterial Hypertension
    Additional relevant MeSH terms:
    Hypertension

    Study Results

    No Results Posted as of Dec 3, 2010